Attached files
| file | filename |
|---|---|
| EX-99.2 - Emmaus Life Sciences, Inc. | v164529_ex99-2.htm |
| EX-99.3 - Emmaus Life Sciences, Inc. | v164529_ex99-3.htm |
| EX-99.1 - Emmaus Life Sciences, Inc. | v164529_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of Earliest Event Reported): November 2,
2009
CNS
RESPONSE, INC.
(Exact
name of Company as specified in its charter)
|
Delaware
|
0-26285
|
87-0419387
|
||
|
(State
or other
jurisdiction
of
incorporation)
|
(Commission
File No.)
|
(I.R.S.
Employer
Identification
No.)
|
2755
Bristol Street, Suite 285
Costa
Mesa, CA 92626
(Address
of principal executive offices)
(714)
545-3288
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01 Other
Events.
On
November 3, 2009, CNS Response, Inc. (the “Company”) issued a press release
reporting the results of a study presented by Charles DeBattista, D.M.H, M.D.,
at the U.S. Psychiatric and Mental Health Congress. A copy of the
press release is included as Exhibit 99.1 to this Form 8-K and is incorporated
herein by reference. A copy of the poster presented by Dr. DeBattista
on November 2, 2009 at the U.S. Psychiatric and Mental Health Congress is
included as Exhibit 99.2 to this Form 8-K and is incorporated herein by
reference.
The
Company will be holding a conference call to discuss the top-line results of its
recently completed study. CNS stockholders are encouraged to participate in the
conference call, which will be held today at 8:00 a.m. PST. Please call Suzanne
Schnitzer at 949.553.9748 to register for the call. You will be given the
toll-free dial-in number and access code to the conference call, along with the
login instructions to join the simultaneous web conference. A copy of
the materials to be presented by the Company over the web are included as
Exhibit 99.3 to this Form 8-K and are incorporated herein by
reference.
Item
9.01 Financial
Statements and Exhibits.
(d) Exhibits
The
following exhibits are filed herewith:
|
99.1
|
Press
Release Issued November 3, 2009.
|
|
99.2
|
Copy
of poster presented at U.S. Psychiatric and Mental Health
Congress.
|
|
99.3
|
Copy
of web presentation
materials.
|
SIGNATURES
Pursuant
to the Securities Exchange Act of 1934, as amended, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
CNS
Response, Inc.
|
||
|
By:
|
/s/
George Carpenter
|
|
|
November
3, 2009
|
George
Carpenter
|
|
|
Chief
Executive Officer
|
||
Exhibit
Index
|
99.1
|
Press
Release Issued November 3, 2009.
|
|
99.2
|
Copy
of poster presented at U.S. Psychiatric and Mental Health
Congress.
|
|
99.3
|
Copy
of web presentation
materials.
|